Identifying in the presence of an SARS-CoV-2, infection of COVID-19 in a human subject and/or for classifying the risk of such infection progressing to a severe or critical disease, using a system functionally associated with at least one analyzer for analyzing the blood sample, is disclosed. The system includes at least one of an input interface or a transceiver, and one or more processors functionally associated therewith. A storage medium associated with the processor(s) has stored instructions to receive biographical information relating to the human subject, and instructions to receive measurements of a plurality of serum biomarkers. Further stored are instructions to apply a neural network algorithm to the measurements of the plurality of biomarkers and the biographical information, and instructions to identify, based on an output of the neural network algorithm, a COVID-19 infection or to classify the risk of such infection progressing to a severe or critical disease.

The presently disclosed fluidic sensor system and method comprise multifunctional nanoprobe-enabled capture for early detection of chemical and/or biological pathogens in a liquid sample. This sensor system and method can be used for food and environmental monitoring.

Methods of identifying a subject with a Filovirus infection are provided herein. In some embodiments, the method comprises contacting a biological sample containing antibodies from the subject with one or more peptides comprising amino acid sequences of selected Filovirus epitopes, detecting the presence or absence of an immune complex of antibodies from the biological sample with the one or more peptides; and wherein the presence of the immune complex identifies the subject as having Filovirus infection and the absence of the immune complex identifies the subject as not having Filovirus infection. Further provided are isolated peptides for use in such methods, as well as a solid support linked to one or more of the disclosed peptides.

The present disclosure is directed to antibodies binding to and neutralizing ebolavirus and methods for use thereof. The present disclosure is directed to a method of detecting an ebolavirus infection in a subject comprising (a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Table 2, or an antibody fragment thereof; and (b) detecting ebolavirus glycoprotein in said sample by binding of said antibody or antibody fragment to antigen in said sample. In still further embodiments, the present disclosure concerns immunodetection kits for use with the iminunodetection methods described above.

A kit, composition and method for detection of antibodies to severe acute respiratory syndrome related coronavirus (SARSr-CoV), and for diagnosis of SARSr-CoV infection.

This disclosure provides antibodies and antigen-binding fragments that are derived from 6nb6 and that can be administered to an individual that is infected or suspected of being infected with a virus. Antibodies and antigen-binding fragments herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies and antigen-binding fragments herein can be used to diagnose a SARS CoV 2 infection.

The presently-disclosed subject matter relates to crosslinkers, compositions, and methods for trapping a target of interest on a substrate of interest. The methods may be used to inhibit and treat pathogen infection and provide contraception. The methods may be used to trap or separate particles and other substances. The subject matter further relates to methods of identifying and preparing optimal crosslinkers and methods for manipulating targets of interest.

The present invention relates to recombinantly constructed proteins useful for analytical assays, in particular for determining in a biological sample obtained from an individual the presence of antibodies specific for a rhabdovirus. More particular, the present invention relates to a polypeptide comprising an ectodomain of a rhabdovirus glycoprotein and a heterologous multimerization domain linked to said ectodomain. In one example, a fusion protein of the formula x-y-z is provided, wherein x consists of or comprises such an ectodomain being optionally free of a furin cleavage site, y is a linker moiety, and z is a heterologous multimerization domain optionally selected from the group consisting of immunoglobulin sequence, coiled coil sequence, streptavidin sequence, fibritin sequence, and avidin sequence.

Disclosed is a covalently-linked multilayered three-dimensional matrix comprising capture molecules, linkers and spacers (referred to as a Molecular Net) for specific and sensitive analyte capture from a sample. Also disclosed herein is a Molecular Net comprising covalently-linked multilayered three-dimensional matrix comprising more than one type of capture molecule and more than one type of linker and may comprise one or more spacer for specific and sensitive capture of more than one type of analyte from a sample. A Molecular Net may comprise a pseudorandom nature. Use of various capture molecules, linkers and spacers in a Molecular Net may confer unique binding properties to a Molecular Net. Porosity, binding affinity, size exclusion abilities, filtration abilities, concentration abilities and signal amplification abilities of a Molecular Net may be varied and depend on the nature of components used in its fabrication. Uses of a Molecular Net may include analyte capture, analyte enrichment, analyte purification, analyte detection, analyte measurement and analyte delivery. Molecular Nets may be used in liquid phase or on solid phases such as nanomaterials, modified metal surfaces, nanospheres, microspheres, microtiter plates, slides, pipettes, cassettes, cartridges, discs, probes, lateral flow devices, microfluidics devices, microfluidics devices, optical fibers and others.

A test strip for detecting a serotype O foot-and-mouth disease, the test strip including: a bottom board; a detection layer being disposed on the bottom board and including a detection line and a control line; an absorbent layer being disposed at one end of the detection layer close to the control line; a gold colloidal conjugate pad being disposed at the other side of the detection layer close to the detection line; and a sample pad is disposed on a top of the gold colloidal conjugate pad. The gold colloidal conjugate pad is coated with colloidal gold particles that are conjugated with a Staphylococcus protein A (SPA) marker. The detection line is coated or impregnated with serotype O FMDV-like particles, and the control line is coated or impregnated with rabbit IgG.